Efficacy and Safety of High-Intensity Statins in Japanese Patients After Percutaneous Coronary Intervention ― Insights From the Clinical Deep Data Accumulation System (CLIDAS<sup>®</sup>) ―

  • Matoba Tetsuya
    Department of Cardiovascular Medicine, Kyushu University Hospital
  • Katsuki Shunsuke
    Department of Cardiovascular Medicine, Kyushu University Hospital
  • Nakano Yasuhiro
    Department of Cardiovascular Medicine, Kyushu University Hospital
  • Kawahara Takuro
    Department of Cardiovascular Medicine, Kyushu University Hospital
  • Kimura Mitsukuni
    Department of Cardiovascular Medicine, Kyushu University Hospital
  • Hino Rissei
    Department of Cardiovascular Medicine, Kyushu University Hospital
  • Tabuchi Takuya
    Department of Cardiovascular Medicine, Kyushu University Hospital
  • Fukata Mitsuhiro
    Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital
  • Hieda Michinari
    Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital
  • Yamashita Takanori
    Medical Information Center, Kyushu University Hospital
  • Nakashima Naoki
    Department of Medical Informatics, Graduate School of Medical Sciences, Kyushu University
  • Kohro Takahide
    Department of Medical Informatics, Jichi Medical University Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University
  • Kabutoya Tomoyuki
    Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University
  • Oba Yusuke
    Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University
  • Kario Kazuomi
    Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University
  • Imai Yasushi
    Department of Clinical Pharmacology, Jichi Medical University
  • Fujita Hideo
    Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center
  • Akashi Naoyuki
    Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center
  • Kiyosue Arihiro
    Department of Cardiovascular Medicine, The University of Tokyo Cardiology, Moriyama Memorial Hospital
  • Mizuno Yoshiko
    Department of Cardiovascular Medicine, The University of Tokyo Development Bank of Japan Inc.
  • Kodera Satoshi
    Department of Cardiovascular Medicine, The University of Tokyo
  • Nakayama Masaharu
    Department of Medical Informatics, Tohoku University Graduate School of Medicine
  • Nochioka Kotaro
    Division of Cardiovascular Medicine, Tohoku University Hospital
  • Miyamoto Yoshihiro
    Open Innovation Center, National Cerebral and Cardiovascular Center,
  • Iwai Takamasa
    Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center,
  • Tsujita Kenichi
    Department of Cardiovascular Medicine, Kumamoto University
  • Nakamura Taishi
    Department of Cardiovascular Medicine, Kumamoto University Department of Medical Information Science, Kumamoto University
  • Ishii Masanobu
    Department of Cardiovascular Medicine, Kumamoto University Department of Medical Information Science, Kumamoto University
  • Sato Hisahiko
    Precision Inc.
  • Matoba Yuri
    Precision Inc.
  • Nagai Ryozo
    Jichi Medical University

Search this article

Description

<p>Background: Lipid-lowering therapy with high-intensity statins has not been widely implemented in Japan for patients with coronary artery disease who undergo percutaneous coronary intervention (PCI). We examined the efficacy and safety of high-intensity statin therapy in a real-world setting.</p><p>Methods and Results: We used the Clinical Deep Data Accumulation System (CLIDAS) to accumulate multimodal data from the electronic medical records of 7 cardiovascular centers. We analyzed 9,690 patients who underwent PCI between 2013 and 2019 and completed a median 2.5-year follow-up (CLIDAS-PCI database). The risk of developing major adverse cardiac and cerebrovascular events (MACCE) was significantly greater in patients with acute (ACS) than chronic (CCS) coronary syndrome. High-intensity statins were prescribed to 49% of ACS patients and 33% of CCS patients within the first 30 days after the index PCI. After propensity score matching, MACCE event rates were similar between the high- and moderate-intensity statin groups. Importantly, among ACS patients, Cox proportional hazard analysis revealed that the rate of myocardial infarction was lower (adjusted hazard ratio [aHR] 0.65; 95% confidence interval [CI] 0.44–0.97) and the rate of stroke was greater (aHR 1.71; 95% CI 1.12–2.62) in the high-intensity statin group, driven mostly by intracranial hemorrhage.</p><p>Conclusions: The CLIDAS-PCI database provides real-world evidence for the efficacy and safety of high-intensity statins in Japanese ACS patients who have undergone PCI.</p>

Journal

  • Circulation Journal

    Circulation Journal advpub (0), 2025-06-19

    The Japanese Circulation Society

Details 詳細情報について

Report a problem

Back to top